Tianjin TEDA Receives Approval For Biopharma Development Plan
This article was originally published in PharmAsia News
Executive Summary
Tianjin Economic-Technological Development Area has received approval for its biopharmaceutical industry plan, which aims to cultivate biopharmaceuticals as its key industry through a 10-year development plan. By 2015, the industry's output value will reach RMB 50 billion, accounting for 5 percent of TEDA's total value. With more than 200 pharmaceutical enterprises setting up bases, the development area seeks to be an influential drug R&D and manufacturing hub in Asia Pacific by participating in the international industry. TEDA will provide assurances and support for the biopharma sector in eight aspects, namely, system, space, funds, talent, policy, technology, services and resources. (Click here for more - Chinese language)